Decreasing frequency and improved outcomes of hepatitis C-related liver transplantation in the era of direct-acting antivirals – a retrospective cohort study

Sumant S. Arora, Page Axley, Zunirah Ahmed, Sanjaya K. Satapathy, Robert Wong, Yong Fang Kuo, Ashwani K. Singal

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Benefit of direct-acting antivirals (DAA) for hepatitis C virus (HCV) on clinical outcomes is unclear. We examined temporal trends in liver transplant (LT) listings, receipt of LT, re-LT, and survival between pre-DAA (2009–2012) and DAA era (2013–2016) using UNOS database. Of 32 319 first adult LT, 15 049 (47%) were performed for HCV. Trends on listing, first LT, and of re-LT for HCV showed 23%, 20%, and 21% decrease in DAA compared to pre-DAA era (P < 0.0001). One-year liver graft and patient survival among HCV LT improved in DAA era (90% vs. 86% and 92% vs. 88%, respectively, P < 0.0001). Non-HCV LT showed no improvement in survival (89% vs. 89% and 92% vs. 92.4%, P = NS). On cox regression, compared to non-HCV LTs in DAA era, LT for HCV in pre-DAA era had worse patient survival (HR 1.56 [1.04–2.35]). The outcome was similar when compared to LTs for HCV in DAA era and for non-HCV in pre-DAA era. Burden of HCV-related LT waitlist and LT is declining in DAA era, with improved post-transplant outcomes, more so in later than earlier DAA era. Our findings negate recent Cochrane meta-analysis on DAA therapy and encourage studies to examine HCV clinical outcomes outside LT setting.

Original languageEnglish (US)
JournalTransplant International
DOIs
StatePublished - Jan 1 2019

Fingerprint

Hepatitis C
Liver Transplantation
Antiviral Agents
Cohort Studies
Retrospective Studies
Transplants
Hepacivirus
Liver
Viruses
Survival
Graft Survival
Meta-Analysis
Databases

Keywords

  • direct-acting antivirals
  • hepatitis C virus
  • survival
  • waitlist mortality

ASJC Scopus subject areas

  • Transplantation

Cite this

Decreasing frequency and improved outcomes of hepatitis C-related liver transplantation in the era of direct-acting antivirals – a retrospective cohort study. / Arora, Sumant S.; Axley, Page; Ahmed, Zunirah; Satapathy, Sanjaya K.; Wong, Robert; Kuo, Yong Fang; Singal, Ashwani K.

In: Transplant International, 01.01.2019.

Research output: Contribution to journalArticle

@article{56da54aa0ef344d0a98ab18c195f7be0,
title = "Decreasing frequency and improved outcomes of hepatitis C-related liver transplantation in the era of direct-acting antivirals – a retrospective cohort study",
abstract = "Benefit of direct-acting antivirals (DAA) for hepatitis C virus (HCV) on clinical outcomes is unclear. We examined temporal trends in liver transplant (LT) listings, receipt of LT, re-LT, and survival between pre-DAA (2009–2012) and DAA era (2013–2016) using UNOS database. Of 32 319 first adult LT, 15 049 (47{\%}) were performed for HCV. Trends on listing, first LT, and of re-LT for HCV showed 23{\%}, 20{\%}, and 21{\%} decrease in DAA compared to pre-DAA era (P < 0.0001). One-year liver graft and patient survival among HCV LT improved in DAA era (90{\%} vs. 86{\%} and 92{\%} vs. 88{\%}, respectively, P < 0.0001). Non-HCV LT showed no improvement in survival (89{\%} vs. 89{\%} and 92{\%} vs. 92.4{\%}, P = NS). On cox regression, compared to non-HCV LTs in DAA era, LT for HCV in pre-DAA era had worse patient survival (HR 1.56 [1.04–2.35]). The outcome was similar when compared to LTs for HCV in DAA era and for non-HCV in pre-DAA era. Burden of HCV-related LT waitlist and LT is declining in DAA era, with improved post-transplant outcomes, more so in later than earlier DAA era. Our findings negate recent Cochrane meta-analysis on DAA therapy and encourage studies to examine HCV clinical outcomes outside LT setting.",
keywords = "direct-acting antivirals, hepatitis C virus, survival, waitlist mortality",
author = "Arora, {Sumant S.} and Page Axley and Zunirah Ahmed and Satapathy, {Sanjaya K.} and Robert Wong and Kuo, {Yong Fang} and Singal, {Ashwani K.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1111/tri.13424",
language = "English (US)",
journal = "Transplant International",
issn = "0934-0874",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Decreasing frequency and improved outcomes of hepatitis C-related liver transplantation in the era of direct-acting antivirals – a retrospective cohort study

AU - Arora, Sumant S.

AU - Axley, Page

AU - Ahmed, Zunirah

AU - Satapathy, Sanjaya K.

AU - Wong, Robert

AU - Kuo, Yong Fang

AU - Singal, Ashwani K.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Benefit of direct-acting antivirals (DAA) for hepatitis C virus (HCV) on clinical outcomes is unclear. We examined temporal trends in liver transplant (LT) listings, receipt of LT, re-LT, and survival between pre-DAA (2009–2012) and DAA era (2013–2016) using UNOS database. Of 32 319 first adult LT, 15 049 (47%) were performed for HCV. Trends on listing, first LT, and of re-LT for HCV showed 23%, 20%, and 21% decrease in DAA compared to pre-DAA era (P < 0.0001). One-year liver graft and patient survival among HCV LT improved in DAA era (90% vs. 86% and 92% vs. 88%, respectively, P < 0.0001). Non-HCV LT showed no improvement in survival (89% vs. 89% and 92% vs. 92.4%, P = NS). On cox regression, compared to non-HCV LTs in DAA era, LT for HCV in pre-DAA era had worse patient survival (HR 1.56 [1.04–2.35]). The outcome was similar when compared to LTs for HCV in DAA era and for non-HCV in pre-DAA era. Burden of HCV-related LT waitlist and LT is declining in DAA era, with improved post-transplant outcomes, more so in later than earlier DAA era. Our findings negate recent Cochrane meta-analysis on DAA therapy and encourage studies to examine HCV clinical outcomes outside LT setting.

AB - Benefit of direct-acting antivirals (DAA) for hepatitis C virus (HCV) on clinical outcomes is unclear. We examined temporal trends in liver transplant (LT) listings, receipt of LT, re-LT, and survival between pre-DAA (2009–2012) and DAA era (2013–2016) using UNOS database. Of 32 319 first adult LT, 15 049 (47%) were performed for HCV. Trends on listing, first LT, and of re-LT for HCV showed 23%, 20%, and 21% decrease in DAA compared to pre-DAA era (P < 0.0001). One-year liver graft and patient survival among HCV LT improved in DAA era (90% vs. 86% and 92% vs. 88%, respectively, P < 0.0001). Non-HCV LT showed no improvement in survival (89% vs. 89% and 92% vs. 92.4%, P = NS). On cox regression, compared to non-HCV LTs in DAA era, LT for HCV in pre-DAA era had worse patient survival (HR 1.56 [1.04–2.35]). The outcome was similar when compared to LTs for HCV in DAA era and for non-HCV in pre-DAA era. Burden of HCV-related LT waitlist and LT is declining in DAA era, with improved post-transplant outcomes, more so in later than earlier DAA era. Our findings negate recent Cochrane meta-analysis on DAA therapy and encourage studies to examine HCV clinical outcomes outside LT setting.

KW - direct-acting antivirals

KW - hepatitis C virus

KW - survival

KW - waitlist mortality

UR - http://www.scopus.com/inward/record.url?scp=85063538986&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063538986&partnerID=8YFLogxK

U2 - 10.1111/tri.13424

DO - 10.1111/tri.13424

M3 - Article

C2 - 30866110

AN - SCOPUS:85063538986

JO - Transplant International

JF - Transplant International

SN - 0934-0874

ER -